Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL | Q9Y232 | 5/20 | 0.66 |
| ▸ | CBX7 | O95931 | 4/20 | 0.66 |
| ▸ | CDYL2 | Q8N8U2 | 4/20 | 0.66 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386342 | 0.82 | ALDH1A1 (0.75) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL4379269 | 0.81 | ALDH1A1 (0.73) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL12124515 | 0.80 | — | — | |
| SCHEMBL12124405 | 0.78 | — | — | |
| SCHEMBL12124510 | 0.78 | — | — | |
| SCHEMBL12124489 | 0.78 | CBX7 (0.55) | CDYLCBX7CDYL2CDY1; CDY1B | |
| SCHEMBL12124511 | 0.77 | — | — | |
| SCHEMBL12124415 | 0.77 | — | — | |
| SCHEMBL4385817 | 0.75 | ALDH1A1 (0.63) | CDYLCBX7CDYL2CDY1; CDY1BALDH1A1 | |
| SCHEMBL1862937 | 0.73 | CHRM4 (0.56) | CDYLCBX7CDYL2CDY1; CDY1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| EP-2747768-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Cognition Therapeutics, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013029060-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | CDYL 3080/4885CBX7 3383/4885CDYL2 1751/4885 |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | CDYL 3080/4885CBX7 3383/4885CDYL2 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.